Treating inflammation by blocking interleukin-1 in humans.
Treating inflammation by blocking interleukin-1 in humans.
复制标题
DOI：
10.1016/j.smim.2013.10.008
复制
发表时间：
2013-12-15
影响因子：
7.8
通讯作者：
van der Meer JW
中科院分区：
文献类型：
--
作者：
Dinarello CA;van der Meer JW
IL-1是局部和全身炎症的主要细胞因子。随着特异性IL-1靶向治疗的可用性，越来越多的疾病已经揭示了IL-1介导的炎症的病理作用。尽管患者接受IL-1（IL-1α或IL-1β）给药以改善骨髓功能或增加宿主对癌症的免疫反应，但这些患者出现了不可接受的毒性，包括发热、厌食、肌痛、关节痛、疲乏、胃肠道不适和睡眠障碍;发生了明显的低血压。因此，在炎性疾病中特异性药理学阻断IL-1活性将是有益的并不意外。单药治疗阻断广泛的炎症综合征中的IL-1活性导致疾病严重程度的快速和持续降低。在常见的情况下，如心力衰竭和痛风性关节炎，IL-1阻断可以是有效的治疗。三种IL-1阻滞剂已被批准：IL-1受体拮抗剂阿那白滞素（anakinra）可阻断IL-1受体，从而降低IL-1α和IL-1β的活性。可溶性诱饵受体利洛那西普和中和性单克隆抗白细胞介素-1 β抗体卡那单抗也获得批准。一种针对IL-1受体的单克隆抗体和一种中和性抗IL-1α抗体正在临床试验中。通过特异性阻断IL-1，我们已经了解了很多关于这种细胞因子在炎症中的作用，但同样重要的是，降低IL-1活性减轻了许多患者的疾病负担。
IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL-1-mediated inflammation. Although IL-1, either IL-1α or IL-1β, was administered to patients in order to improve bone marrow function or increase host immune responses to cancer, these patients experienced unacceptable toxicity with fever, anorexia, myalgias, arthralgias, fatigue, gastrointestinal upset and sleep disturbances; frank hypotension occurred. Thus it was not unexpected that specific pharmacological blockade of IL-1 activity in inflammatory diseases would be beneficial. Monotherapy blocking IL-1 activity in a broad spectrum of inflammatory syndromes results in a rapid and sustained reduction in disease severity. In common conditions such as heart failure and gout arthritis, IL-1 blockade can be effective therapy. Three IL-1blockers have been approved: the IL-1 receptor antagonist, anakinra, blocks the IL-1 receptor and therefore reduces the activity of IL-1α and IL-1β. A soluble decoy receptor, rilonacept, and a neutralizing monoclonal anti-interleukin-1β antibody, canakinumab, are also approved. A monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α are in clinical trials. By specifically blocking IL-1, we have learned a great deal about the role of this cytokine in inflammation but equally important, reducing IL-1 activity has lifted the burden of disease for many patients.
登录
查看更多内容
影响因子：
6.8
作者：
Abbate, Antonio;Van Tassell, Benjamin W.;Biondi-Zoccai, Giuseppe G. L.
通讯作者：
Biondi-Zoccai, Giuseppe G. L.
中国类风湿关节炎患者重组人IL-1受体拮抗剂治疗继发失败
影响因子：
3.4
作者：
Bao, Jun;Yue, Tao;Dai, Sheng-Ming
通讯作者：
Dai, Sheng-Ming
影响因子：
10.9
作者：
Belani, Hrishikesh;Gensler, Lianne;Leslie, Kieron S.
通讯作者：
Leslie, Kieron S.
影响因子：
3.4
作者：
Ahmadi, Neda;Brewer, Carmen C.;Kim, H. Jeffrey
通讯作者：
Kim, H. Jeffrey
DOI：
10.1056/nejmoa0807865
发表时间：
2009-06-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Aksentijevich I;Masters SL;Ferguson PJ;Dancey P;Frenkel J;van Royen-Kerkhoff A;Laxer R;Tedgård U;Cowen EW;Pham TH;Booty M;Estes JD;Sandler NG;Plass N;Stone DL;Turner ML;Hill S;Butman JA;Schneider R;Babyn P;El-Shanti HI;Pope E;Barron K;Bing X;Laurence A;Lee CC;Chapelle D;Clarke GI;Ohson K;Nicholson M;Gadina M;Yang B;Korman BD;Gregersen PK;van Hagen PM;Hak AE;Huizing M;Rahman P;Douek DC;Remmers EF;Kastner DL;Goldbach-Mansky R
通讯作者：
Goldbach-Mansky R